Vivos (RDGL) Other financing activities (2011 - 2025)

Vivos (RDGL) posted Other financing activities of $1500.0 for Q1 2025, down 85.0% sequentially from $10000.0 in Q2 2018.

Vivos (RDGL) Other financing activities (2011 - 2025) Analysis & Trends

Vivos has reported Other financing activities for 7 years, with the latest figure at $1500.0 in Q1 2025.

Quarterly Other financing activities changed N/A year-over-year to $1500.0 in Q1 2025, while the trailing twelve-month figure through Dec 2025 was $1500.0 (changed N/A YoY) and the FY2025 annual result came in at $1500.0, down 92.25% from the prior year.
Other financing activities declined to $1500.0 in Q1 2025 per RDGL's latest filing, from $10000.0 in the prior quarter.
Over five years, Other financing activities peaked at $1500.0 in Q1 2025 and troughed at $1500.0 in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	198.70 Bn	193.10 Bn	7.27 Bn
2	Stryker	125.85 Bn	122.37 Bn	4.50 Bn
3	Medtronic	118.44 Bn	109.22 Bn	6.41 Bn
4	Boston Scientific	72.64 Bn	72.10 Bn	3.85 Bn
5	Edwards Lifesciences	51.94 Bn	47.69 Bn	1.35 Bn
6	Dexcom	34.48 Bn	32.53 Bn	830.00 Mn
7	GE HealthCare Technologies	33.60 Bn	31.49 Bn	2.18 Bn
8	Koninklijke Philips	26.30 Bn	22.98 Bn	4.55 Bn
9	Steris	23.00 Bn	22.52 Bn	684.20 Mn
10	Vivos	24.08 Mn	22.53 Mn	-3,105.00

Download Data